نتایج جستجو برای: bacillus calmette

تعداد نتایج: 57420  

Journal: :Asian journal of surgery 2007
Azad H A Razack

Bladder cancer is the second most common cancer of the urinary tract, and overall it is among the top 10 cancers in men. Transitional cell carcinoma (TCC) is the most common type, with the majority being superficial disease, i.e. the tumour has not gone beyond the lamina propria. The main problem with superficial TCC is the high recurrence rate. Various forms of treatment methods have been atte...

2012
Yi Luo

Proper induction of Th1 immunity is required for effective immunotherapy of bladder cancer with the bacillus Calmette-Guérin (BCG). Interleukin-10 (IL-10) downregulates the Th1 immune response and is associated with BCG therapy failure. We evaluated BCG plus IL-10 blocking antibodies and found that this combination therapy induces enhanced Th1 immune responses and anti-bladder cancer immunity i...

Journal: :European urology 2015
A Hugh Mostafid Joan Palou Redorta Richard Sylvester J Alfred Witjes

Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.

2017

Submit Manuscript | http://medcraveonline.com Abbreviations: NDV: Newcastle Disease Virus; APMV-1: Avian Paramyxovirus Type I; IFN: Interferon; CTLA-4: Cytotoxic T Lymphocyte Associated Antigen-4; RCC: Renal Cell Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; IL-2: Interleukin-2; DTH: Delayed Type Hypersensitivity; Gy: Gray; BCG: Bacillus Calmette-Guerin; HN: Hemagglutinin-Neuraminida...

2013
Sun Myung Joung Sung Joo Jeon Young Ju Lim Jong-Sung Lim Beom-Soon Choi Ik-Young Choi Jeong Hee Yu Kyung-In Na En-Hi Cho Sang-Sook Shin Young Kil Park Chang-Ki Kim Hee-Jin Kim Sung Weon Ryoo

Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only vaccine available against tuberculosis, and the strains used worldwide represent a family of daughter strains with distinct genotypic characteristics. Here, we report the complete genome sequence of M. bovis BCG Korea, the strain that will be actually used in Korea for vaccine production.

Journal: :Journal of clinical microbiology 2005
Tatsuma Okazaki Satoru Ebihara Hidenori Takahashi Masanori Asada Akimasa Sato Masaaki Seki Hideyasu Ohto Hidetada Sasaki

This is the first identified case of Mycobacterium bovis bacillus Calmette-Guerin (BCG)-derived cutaneous tuberculosis that localizes at a place different from the vaccination site in hosts without immune deficiency. A healthy baby with a developing abscess is described. A multiplex PCR identified the abscess as originating from M. bovis BCG Tokyo 172.

2016
Johannes Breyer Maximilian Burger Wolfgang Otto

Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets.

2012
Goodwin Jinesh G. Ashish M. Kamat

Intravesical bacillus Calmette-Guérin (BCG) immunotherapy results in neutrophil recruitment and subsequent secretion of cytokines to eliminate non-muscle invasive bladder cancer cells. However, bladder cancer cells often resist BCG immunotherapy. Thus, understanding the mechanism of action of BCG, and designing appropriate combination therapies might help to overcome BCG resistance and redirect...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید